Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12710484 | 0.85 | MAPT (0.58) | MAPTALDH1A1HCAR2ATM | |
| SCHEMBL8085681 | 0.81 | HCAR2 (0.44) | MAPTALDH1A1HCAR2ATM | |
| SCHEMBL5611325 | 0.81 | HCAR2 (0.44) | MAPTALDH1A1HCAR2ATM | |
| SCHEMBL5611334 | 0.81 | HCAR2 (0.44) | MAPTALDH1A1HCAR2ATM | |
| SCHEMBL13433290 | 0.80 | HCAR2 (0.48) | MAPTALDH1A1HCAR2 | |
| SCHEMBL17522209 | 0.76 | MAPT (0.33) | MAPTHCAR2ATM | |
| SCHEMBL10943665 | 0.75 | GSTP1 (0.38) | ALDH1A1HCAR2ATM | |
| SCHEMBL9004563 | 0.75 | GSTP1 (0.38) | ALDH1A1HCAR2ATM | |
| SCHEMBL15794884 | 0.75 | HCAR2 (0.35) | ALDH1A1HCAR2ATM | |
| SCHEMBL24004712 | 0.74 | MAPT (0.40) | MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-20 | — | — | US | disclosed |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2021-04-01 | — | — | US | disclosed |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RAPAFUSYN PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | MAPT 3230/4885ALDH1A1 4678/4885HCAR2 1382/4885 |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | MAPT 3230/4885ALDH1A1 4678/4885HCAR2 1382/4885 |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | MAPT 3230/4885ALDH1A1 4678/4885HCAR2 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.